Abstract: The invention relates to liposomes, methods of producing liposomes, and methods of loading cell-derived liposomes with cargo molecules. The invention extends to such liposomes per se, and to the use of these liposomes as cellular delivery systems for the delivery of biologically and therapeutically active payload molecules, such as small molecules, RNAi molecules (e.g. siRNA), bioactive proteins, genome editing tools (e.g. Cas9) and drugs into cells for treating a range of disorders. The liposomes may also be used in a range of diagnostic and theranostic applications. The invention extends to pharmaceutical compositions comprising such liposomes, including populations of extracellular vesicles (EV), exosomes and to fusion proteins.

Abstract: An apparatus, method and computer program is described, comprising: rotating a rotatable frame within a liquid provision chamber; providing liquid to a sample on the rotatable frame; obtaining a plurality of images of the sample from a plurality of angles over a first time period; and obtaining a three-dimensional model of the sample based on said plurality of images, wherein the three-dimensional model of the sample comprises quantitative information regarding at least one effect on the sample over the first time period in response to the provision of the liquid.

Abstract: The invention relates to liposomes, methods of producing liposomes, and methods of loading cell-derived liposomes with cargo molecules. The invention extends to such liposomes per se, and to the use of these liposomes as cellular delivery systems for the delivery of biologically and therapeutically active payload molecules, such as small molecules, RNAi molecules (e.g. siRNA), bioactive proteins, genome editing tools (e.g. Cas9) and drugs into cells for treating a range of disorders. The liposomes may also be used in a range of diagnostic and theranostic applications. The invention extends to pharmaceutical compositions comprising such liposomes, including populations of extracellular vesicles (EV), exosomes and to fusion proteins.

Abstract: An insect trap (100) and method for trapping and/or killing insects are disclosed. The insect trap comprises an enclosure (10) for receiving a human or an animal, and comprising an opening (12) configured to allow air to flow out of the enclosure and prevent insects from entering the enclosure, and a trapping unit (30) outside of the enclosure and in fluidic communication with the opening. The trapping unit comprises a heatable container (32) comprising either an adhesive material (31) for attracting and trapping an insect or a material comprising insecticide for killing an insect.

Abstract: The invention relates to a process of preparing a salt of an active pharmaceutical ingredient, the process comprising providing a blend of an active pharmaceutical ingredient and a salt forming substance, mixing the blend, optionally in the presence of added water, to react the active pharmaceutical ingredient with the salt forming substance to provide the salt of the active pharmaceutical ingredient; wherein when the active pharmaceutical ingredient is acidic, the salt forming substance is a base and the pKa difference between the acidic active pharmaceutical ingredient and the base is greater than 1, typically greater than 2 or preferably greater than 3; or when the active pharmaceutical ingredient is basic, the salt forming substance is an acid and the pKa difference between the basic active pharmaceutical ingredient and the acid is greater than 1, typically greater than 2 or preferably greater than 3.

Abstract: The invention provides a method of manufacturing a stent (12) using a three dimensional (3D) printer. The invention also extends to 3D printed stents and second medical uses of such stents. The invention also extends to electric signals carrying computer-executable instructions adapted to cause a 3D printer to print a stent, computer-readable programs and computer-readable mediums.

Abstract: The invention provides a method of manufacturing a stent (12) using a three dimensional (3D) printer. The invention also extends to 3D printed stents and second medical uses of such stents. The invention also extends to electric signals carrying computer-executable instructions adapted to cause a 3D printer to print a stent, computer-readable programs and computer-readable mediums.

Abstract: A method of treating a disorder. The method includes administering to a subject in need thereof a compound of general formula (I): Each of A, N*, X, Y, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

Abstract: A method of treating a disorder. The method includes administering to a subject in need thereof a compound of general formula (I): Each of A, N*, X, Y, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

Abstract: An attractant composition suitable for attracting Lepidopterous insects, particularly Helicoverpa armigera, for use as an insect lure in a control method aimed at reducing pest damage to crops. The preferred attractant composition comprises phenylacetaldehyde, salicylaldehyde and at least one compound selected from the group comprising: methyl-2-methoxybenzoate, linalool and limonene.

Abstract: Microneedle devices are spray coated by nozzles which jet dispense dots onto the individual needles of a microneedle device from a spray nozzle which is angled with respect to the plane of the microneedle device. An angle of between 70° and 45° is preferred and can be achieved by providing the microneedle devices on a support which is inclined at 20° to 45° to the horizontal and using a spray nozzle with a vertical axis.

Abstract: A method of identifying the biotype (or clade) of a whitefly comprising using at least one of: (a) an hsp90 gene, polypeptide or protein, (b) an enolase gene, polypeptide or protein, (c) a fructose bisphosphate aldolase gene, polypeptide or protein, (d) a triose phosphate isomerase gene, polypeptide or protein, or (e) a vitellogenin gene, polypeptide or protein, of the whitefly. A kit for identifying B. tabaci biotype Asia is also provided as well as isolated polynucleotides and polypeptides having SEQ ID 10 NOs: 1-9, and polynucleotides and antibodies that bind SEQ ID NOs: 1-9.

Abstract: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula I: in which R1 is a halo-alkyl group and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system, or a pharmaceutically acceptable salt or solvate thereof.

Abstract: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula I: in which R1 is a halo-alkyl group and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system, or a pharmaceutically acceptable salt or solvate thereof.

Abstract: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The triazine compounds are of formula (I) wherein: R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when R1 is hydrogen or ?NH when R1 is a substituent group; R3 and R4 are both carbocyclic, heterocyclic or alkyl groups and may be same or different; and R5 is hydrogen, alkyl or a cyclic aryl group, with the proviso that: when R3 and R4 are both alkyl they are linked to form a cycloalkyl group, and R5 is a cyclic aromatic group; and when R3 and R4 are both carbocyclic or heterocyclic groups, R5 is hydrogen or an alkyl group; or a salt thereof.

Abstract: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula (I): in which z is a single bond or an optionally substituted linking group, R1 is a halo-alkyl group; and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system; or a salt thereof.

Abstract: A method of treating a disorder. The method includes administering to a subject in need thereof a compound of formula (I): Each of A, N*, X, Y, Z, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

Abstract: Compounds of general structure in which X and Y are each N or C with at least one of X and Y being N; Z is a single bond or an optionally substituted linking group R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when RI is hydrogen or ?NH when R1 is a substituent group; or N* is a group NRaRb where Ra and Rb are independently H or an alkyl group; or N* is an optionally substituted piperazinyl ring; and A is an optionally substituted heterocyclic or carbocyclic ring system which may be linked to the triazo/diazo ring through R2 to form a fused multicyclic ring; are indicated as suitable for treatment of disorders in mammals that are susceptible to sodium channel blockers and antifolates, and particularly disorders such epilepsy, multiple sclerosis, glaucoma and uevitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motorneurone disease, Alzheimer's disease, Parkinson's disease, chronic infl

Abstract: The present invention relates to restorative materials, in particular to glass-ionomer cements. More particularly, the present invention relates to glass-ionomer cements having particular utility in the repair of human hard tissue, in particular as dental restorative materials and in orthopaedic surgery. We describe a composition comprising a mixture of a glass ionomer cement and zinc phosphate. Preferably, the composition comprise from 40 to 95% by weight of glass ionomer cement and from to 60% by weight of zinc phosphate. The present invention also provides a powdered composition comprising a fluorosilicate glass and deactivated zinc oxide. Such that the zinc phosphate is formed in sith by reaction between the zinc oxide and phosphoric acid.

Abstract: Method of generating partitions of a communications network A population of partitions S0,S1, . . . of a communication network (312) having different optimisation objectives are generated in a cascading manner. A preferred solution or partition can be selected from the population and the communications network (312) can be configured accordingly.